Sisson J C, Shapiro B, Hutchinson R J, Zasadny K R, Mallette S, Mudgett E E, Wieland D M
Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028.
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):255-9.
To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy.
